agalsidase beta, a miscellaneous agent used intravenously to treat Fabry’s disease. It lowers the amount of globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells in patients with Fabry’s disease. See Fabry’s disease. ▪ CONTRAINDICATIONS: Known hypersensitivity to this drug prohibits its use.▪ PATIENT CARE CONSIDERATIONS: Infusion reactions are not uncommon and can be severe.
